Screening for liver disease in cystic fibrosis: Analysis of clinical and genetic risk factors for its development

Turkish Journal of Pediatrics

Volumn 50, Issue 6, 2008, Pages 526-532

  Fustik, Stojka ^a   Trajkovska, Meri ^a   Jakovska, Tanja ^a   Spirevska, Lidija ^a   Josifovska, Tanja ^b   Koceva, Svetlana ^a  

^a MACEDONIAN ACADEMY OF SCIENCES AND ARTS   (Macedonia)

^b SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

Cystic fibrosis; Genotype; Hepatobiliary scintigraphy; Liver disease; Screening; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADOLESCENT; ARTICLE; BIOCHEMISTRY; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEPATOMEGALY; HEREDITY; HUMAN; LIVER DISEASE; MACEDONIA (REPUBLIC); MAJOR CLINICAL STUDY; MALE; MECONIUM ILEUS; NUTRITIONAL STATUS; PATHOGENESIS; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PREVALENCE; RISK FACTOR; SCHOOL CHILD; SCINTIGRAPHY; SCREENING; SPLENOMEGALY;

ADOLESCENT; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENOTYPE; HUMANS; LIVER DISEASES; MALE; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 62749086668     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr Suppl 1999; 28: 1-13.
2. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics 1999; 103: 52-58.
3. Colombo C, Battezzati PM, Padda M, Battezzati N, Giunata A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996; 23: 1484-1490.
4. Scott-Jupp R, Lamo M, Touner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991; 66: 698-701.
5. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975; 86: 683-689.
6. Vawter GF, Shwachman H. Cystic fibrosis in adults: an autopsy study. Pathol Ann 1979; 14: 357-382.
7. Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee J, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995; 22: 513-521.
8. Petreska L, Koceva S, Plaseska D, et al. Molecular basis of cystic fibrosis in the Republic of Macedonia. Clin Genet 1998; 54: 203-209.
9. Koceva S, Plaseska D, Fustik S, Caparevska M, Efremov GD. Cystic fibrosis in Macedonia: an update. BJMG 2001; 4: 47-51.
10. Efrati O, Barak A, Modan-Moses D, et al. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003; 15: 1073-1078.
11. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105: 1857-1864.
12. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994; 124: 394-399.
13. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36: 1374-1382.
14. Slicker MG, Deckers-Kocken JM, Uttervaal CS, van der Ent CK, Houwen RH. Risk factors for the development of cystic fibrosis-related liver disease. Hepatology 2003; 38: 775-776.
15. Lenaerts C, Lapierre C, Patriquin H, et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr 2003; 143: 343-350.
16. Corbett K, Kelleher S, Rowland M, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004; 145: 327-332.
17. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30: 1151-1158.
18. Gaskin KJ, Waters DL, Howman-Giles R, et al. Liver disease and common bile-duct stenosis in cystic fibrosis. N Engl J Med 1988; 318: 340-346.
19. Nagel RA, Westaby D, Javaid A, Meire HB. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989; 2: 1422-1425.
20. O'Brien S, Keogan M, Casey M. Biliary complications of cystic fibrosis. Gut 1992; 33: 387-391.
21. Duthie A, Doherthy DG, Williams C, et al. Genotype analysis for DF508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without liver disease. Hepatology 1992; 15: 660-664.
22. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis - therapeutic implications and long term follow up. Arch Dis Child 1993; 68: 653-657.
23. Duthie A, Doherty DG, Donaldson PT. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995; 23: 532-537.
24. Wastaby D. Liver and biliary disease in cystic fibrosis. In: Hodson ME, Geddes DM (eds). Cystic Fibrosis (2nd ed). London: Arnold; 2000: 287-300.
25. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004; 6: 231-239.
26. Williams SM, Goodman R, Thomson A, Mchugh K, Lindsell DR. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002; 57: 365-370.
27. O'Connor PJ, Sounthern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatic scintigraphy in cystic fibrosis. Hepatology 1996; 23: 281-287.
28. Fustik S, Josifovska T, Pop-Jordanova N, et al. Liver disease in cystic fibrosis. Contributions, Sec. Bilol. Med. Sci. 2000; XXI/1-2: 29-40.
29. Nausia-Avranitakis S, Fountoulaki M, Economou H, Xefteri M, Galli-Tsinopoulou A. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis related liver disease. J Clin Gastroenterol 2001; 32: 324-328.
30. Linblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis- associated liver disease. Hepatology 1998; 27: 166-174.
31. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? J Pediatr Gastroenterol Nutr 1997; 25: 32-36.